Can I make the biggest mistake of my life in peace and quiet...

First 93 Last

Share
Profile

Follow
Ericsson

329 Posts.

120

20/12/22

20:05

Post #: 65389613
Share

Originally posted by whytee: ↑

Well at least he attempts an in depth analysis based around the facts that have been disclosed.

Its way better than the personal attacks and sniping from people who have blind faith and make no effort to discern what's going in anything approaching a realistic appraisal of facts.

But the facts are these:

1. The company received a CRL on their first submission of the BLA

2. The company's description of the control group in the aGVHD wasn't accurate and as the result, the FDA didn't accept the single arm trial result as valid.

3. The company said it would resubmit the BLA addressing all the problems raised by the FDA 2 years ago. It hasn't done so yet.

4. The company is accused of misleading investors about the quality of the trial results and prospects for approval in multiple class action law suits in the USA and Australia. Most are still in progress and one was settled out of court for $2m.

5. It was leaked by one of the company's officers that they had problems with the new potency assay they were going to submit to the FDA, and they have had to revert to the original one.

6. The company has further said it has to rely on the "totality of the evidence" in the hope of persuading the FDA to give limited approval.

7. $30m of the funds the company says are available credit will cease to exist in a week or so as the funding agreement expires on Dec 31.

8. The company loses around $80-$100m every year and needs to keep around $60m in available cash to meet loan covenants and operating expenses. By early next year they will probably need to address funding.

9. Major partners/investors such as TEVA and Novartis have walked away

10. Every major trial the company has been involved with has failed to achieve the primary end points.

It's just hard to find anything that would give investors a real chance to get their money back. The only thing in its favour is the loyalty of a small hard core of faithful investors hoping to redeem their losses. The company's track record of actual achievement doesn't give any real cause for comfort.

Expand

Can I make the biggest mistake of my life in peace and quiet please. lol

MSB Price at posting: 92.5¢ Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

DRE

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

There are more pages in this discussion • 147 more messages in this thread...

First 93 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.19		Change 0.015(1.28%)		Mkt cap ! $1.353B

Open	High	Low	Value	Volume
$1.17	$1.22	$1.17	$4.112M	3.471M

Buyers (Bids)

No.	Vol.	Price($)
33	29200	$1.18

Sellers (Offers)

Price($)	Vol.	No.
$1.19	52347	9

View Market Depth

No.	Vol.	Price($)
11	17839	1.180
24	45521	1.175
21	139620	1.170
8	44554	1.165
9	152646	1.160

Price($)	Vol.	No.
1.185	69400	6
1.190	56585	10
1.195	84120	14
1.200	229426	15
1.205	37475	5

Last trade - 15.03pm 01/10/2024 (20 minute delay)

MSB (ASX) Chart

Can I make the biggest mistake of my life in peace and quiet...

Failure to report prompts ASX to impose multiple company suspensions

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Can I make the biggest mistake of my life in peace and quiet...

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Dreadnought (ASX:DRE) reports gold hit above 27 grams per tonne

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News